News of Note—Kite IND, RXi I-O targets and Mitobridge DMD test

Kite's IND, RXi's I-O picks and Mitobridge phase 1.

Kite Pharma, which in a tight race with Novartis to gain U.S. approval for the first-ever CAR-T med later this year, said it has submitted an IND app with the FDA for a Phase 1, first-in-human trial of KITE-585, another of its CAR-T therapies, to target B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma. Release

> RNAi company RXi Pharmaceuticals said it has picked two self-delivering RNAi (sd-rxRNA) compounds from its immuno-oncology pipeline for preclinical development. The compounds, RXI-762 and RXI-804, suppress the expression of immune checkpoint proteins PD-1 and TIGIT. Statement

Mitobridge says it has hit a “key milestone” with the start of the first-in-human Phase 1 test of its PPAR-delta modulator, MA-0211 in healthy volunteers, which will provide the basis for future studies in Duchenne Muscular Dystrophy patients. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.